{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:52:49Z","timestamp":1791496369196,"version":"4.3.4"},"reference-count":88,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The World Health Organization Classification of Lymphoid Neoplasms identifies Burkitt lymphoma\/leukemia as a highly aggressive mature B-cell neoplasm consisting of endemic, sporadic, and immunodeficiency-associated variants. These subtypes share many morphologic and immunophenotypic features, but differences exist in their clinical and geographic presentations. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of Burkitt lymphoma that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Brief-duration, high-intensity chemotherapy regimens containing aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease, with complete remission rates of 75% to 90% and overall survivals reaching 50% to 70% in adults. Although Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should be developed because current treatment options are suboptimal for patients with poor prognostic features or in the setting of relapsed disease.<\/jats:p>","DOI":"10.1182\/blood-2004-02-0405","type":"journal-article","created":{"date-parts":[[2004,7,20]],"date-time":"2004-07-20T21:12:04Z","timestamp":1090357924000},"page":"3009-3020","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":451,"title":["Adult Burkitt leukemia and lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"Kristie A.","family":"Blum","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Oncology, The Ohio State University, Columbus; the Division of Pathology, The Ohio State University, Columbus; and the Division of Medicinal Chemistry, Department of Pharmacy, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, The Ohio State University, Columbus; the Division of Pathology, The Ohio State University, Columbus; and the Division of Medicinal Chemistry, Department of Pharmacy, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, The Ohio State University, Columbus; the Division of Pathology, The Ohio State University, Columbus; and the Division of Medicinal Chemistry, Department of Pharmacy, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300191725300_REF1","doi-asserted-by":"crossref","unstructured":"Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46: 218-223.","DOI":"10.1002\/bjs.18004619704"},{"key":"2020021300191725300_REF2","unstructured":"Lukes R, Collins R. New approaches to the classification of the lymphomata. Br J Cancer. 1975; 31: 1-28."},{"key":"2020021300191725300_REF3","doi-asserted-by":"crossref","unstructured":"Non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma: summary and description of a working formulation for clinical usage. Cancer. 1982;49: 2112-2135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"2020021300191725300_REF4","doi-asserted-by":"crossref","unstructured":"Bennett J, Catovsky D, Daniel M, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Int Med. 1985; 103: 620-625.","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"2020021300191725300_REF5","doi-asserted-by":"crossref","unstructured":"Harris N, Jaffe E, Diebold J, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2020021300191725300_REF6","doi-asserted-by":"crossref","unstructured":"Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990;55: 133-270.","DOI":"10.1016\/S0065-230X(08)60470-4"},{"key":"2020021300191725300_REF7","unstructured":"Diebold J, Jaffe E, Raphael M, Warnke R. Burkitt lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 181-184."},{"key":"2020021300191725300_REF8","doi-asserted-by":"crossref","unstructured":"Davi F, Delecluse H, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. J Clin Oncol. 1998;16: 3788-3795.","DOI":"10.1200\/JCO.1998.16.12.3788"},{"key":"2020021300191725300_REF9","doi-asserted-by":"crossref","unstructured":"Mead G, Sydes M, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13: 1264-1274.","DOI":"10.1093\/annonc\/mdf253"},{"key":"2020021300191725300_REF10","doi-asserted-by":"crossref","unstructured":"McMaster M, Greer J, Greco A, Johnson D, Wolff S, Hainsworth J. Effective treatment of small-non-cleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991;9: 941-946.","DOI":"10.1200\/JCO.1991.9.6.941"},{"key":"2020021300191725300_REF11","doi-asserted-by":"crossref","unstructured":"Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85: 664-674.","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664"},{"key":"2020021300191725300_REF12","unstructured":"Frappaz D, Miron I, Brunat-Mentigny M, et al. Is there still a place for initial surgery in advanced Burkitt's lymphoma (BL)? Proc Am Soc Clin Oncol [abstract]. 1995;14: 1295."},{"key":"2020021300191725300_REF13","doi-asserted-by":"crossref","unstructured":"Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361-1392.","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"2020021300191725300_REF14","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood. 1997;89: 3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2020021300191725300_REF15","doi-asserted-by":"crossref","unstructured":"Yano T, van Krieken JHJM, Magrath I, Longo D, Jaffe E, Raffeld M. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood. 1992;79: 1282-1290.","DOI":"10.1182\/blood.V79.5.1282.1282"},{"key":"2020021300191725300_REF16","doi-asserted-by":"crossref","unstructured":"Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17: 1558-1567.","DOI":"10.1200\/JCO.1999.17.5.1558"},{"key":"2020021300191725300_REF17","doi-asserted-by":"crossref","unstructured":"Chapman C, Zhou J, Gregory C, Rickinson A, Stevenson F. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood. 1996;88: 3562-3568.","DOI":"10.1182\/blood.V88.9.3562.bloodjournal8893562"},{"key":"2020021300191725300_REF18","doi-asserted-by":"crossref","unstructured":"Chapman C, Mockridge C, Rowe M, Rickinson A, Stevenson F. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood. 1995;85: 2176-2181.","DOI":"10.1182\/blood.V85.8.2176.bloodjournal8582176"},{"key":"2020021300191725300_REF19","doi-asserted-by":"crossref","unstructured":"Chapman C, Wright D, Stevenson F. Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma. 1998;30: 257-267.","DOI":"10.3109\/10428199809057539"},{"key":"2020021300191725300_REF20","doi-asserted-by":"crossref","unstructured":"Elache V, Magnac C, Pritsch O, et al. Complete nucleotide sequence of IgV genes in three cases of Burkitt lymphoma associated with AIDs. Leuk Lymphoma. 1996;20: 281-290.","DOI":"10.3109\/10428199609051619"},{"key":"2020021300191725300_REF21","doi-asserted-by":"crossref","unstructured":"Hecht J, Aster J. Molecular biology of Burkitt's lymphoma. J Clin Oncol. 2000;18: 3703-3721.","DOI":"10.1200\/JCO.2000.18.21.3707"},{"key":"2020021300191725300_REF22","doi-asserted-by":"crossref","unstructured":"Neri A, Barriga F, Knowles D, Magrath I, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt's lymphoma. Proc Natl Acad Sci U S A. 1988;85: 2748-2752.","DOI":"10.1073\/pnas.85.8.2748"},{"key":"2020021300191725300_REF23","doi-asserted-by":"crossref","unstructured":"Gerbitz A, Mautner J, Geltinger C, et al. Deregulation of the proto-oncogene c-myc through t(8; 22) translocation in Burkitt's lymphoma. Oncogene. 1999;18: 1745-1753.","DOI":"10.1038\/sj.onc.1202468"},{"key":"2020021300191725300_REF24","doi-asserted-by":"crossref","unstructured":"Boxer L, Dang C. Translocations involving c-myc and c-myc function. Oncogene. 2001;20: 5595-5610.","DOI":"10.1038\/sj.onc.1204595"},{"key":"2020021300191725300_REF25","doi-asserted-by":"crossref","unstructured":"Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood. 1991;77: 1516-1526.","DOI":"10.1182\/blood.V77.7.1516.1516"},{"key":"2020021300191725300_REF26","doi-asserted-by":"crossref","unstructured":"Gutierrez M, Bhatia K, Barriga F, et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood. 1992;79: 3261-3266.","DOI":"10.1182\/blood.V79.12.3261.3261"},{"key":"2020021300191725300_REF27","doi-asserted-by":"crossref","unstructured":"Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood. 1994;84: 883-888.","DOI":"10.1182\/blood.V84.3.883.883"},{"key":"2020021300191725300_REF28","doi-asserted-by":"crossref","unstructured":"Lieberson R, Ong J, Shi X, Eckhardt L. Immunoglobulin gene transcription ceases upon deletion of a distant enhancer. EMBO J. 1995;14: 6229-6238.","DOI":"10.1002\/j.1460-2075.1995.tb00313.x"},{"key":"2020021300191725300_REF29","doi-asserted-by":"crossref","unstructured":"Sanchez-Beato M, Sanchez-Agulera A, Piris M. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101: 1220-1235.","DOI":"10.1182\/blood-2002-07-2009"},{"key":"2020021300191725300_REF30","doi-asserted-by":"crossref","unstructured":"Dang C, Resar L, Emison E, et al. Function of the c-Myc oncogenic transcription factor. Exper Cell Res. 1999;253: 63-77.","DOI":"10.1006\/excr.1999.4686"},{"key":"2020021300191725300_REF31","doi-asserted-by":"crossref","unstructured":"Coller H, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that Myc regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000;97: 3260-3265.","DOI":"10.1073\/pnas.97.7.3260"},{"key":"2020021300191725300_REF32","doi-asserted-by":"crossref","unstructured":"Mateyak M, Obaya A, Sedivy J. C-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19: 4672-4683.","DOI":"10.1128\/MCB.19.7.4672"},{"key":"2020021300191725300_REF33","doi-asserted-by":"crossref","unstructured":"Shim H, Dolde C, Lewis B, et al. C-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997; 90: 6658-6663.","DOI":"10.1073\/pnas.94.13.6658"},{"key":"2020021300191725300_REF34","doi-asserted-by":"crossref","unstructured":"Zindy F, Eischen C, Randle D, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12: 2424-2433.","DOI":"10.1101\/gad.12.15.2424"},{"key":"2020021300191725300_REF35","doi-asserted-by":"crossref","unstructured":"Zajac-Kaye M, Levens D. Phosphorylation-dependent binding of a 138-kDa myc intron factor to a regulatory element in the first intron of the c-myc gene. J Biol Chem. 1990;265: 4547-4551.","DOI":"10.1016\/S0021-9258(19)39597-3"},{"key":"2020021300191725300_REF36","doi-asserted-by":"crossref","unstructured":"Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science. 1987;238: 1272-1275.","DOI":"10.1126\/science.3685977"},{"key":"2020021300191725300_REF37","doi-asserted-by":"crossref","unstructured":"Zajac-Kaye M, Gelmann E, Levens D. A point mutation in the c-myc locus of a Burkitt lymphoma abolishes binding of a nuclear protein. Science. 1988;240: 1776-1780.","DOI":"10.1126\/science.2454510"},{"key":"2020021300191725300_REF38","doi-asserted-by":"crossref","unstructured":"Bahram F, von der Lehr N, Cetinkaya C, Larsson L. C-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95: 2104-2110.","DOI":"10.1182\/blood.V95.6.2104"},{"key":"2020021300191725300_REF39","doi-asserted-by":"crossref","unstructured":"Gregory M, Hann S. C-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000;20: 2423-2435.","DOI":"10.1128\/MCB.20.7.2423-2435.2000"},{"key":"2020021300191725300_REF40","unstructured":"Albert T, Burlbauer B, Kohlhuber F, Hammerson B, Eick D. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene. 1994;9: 759-763."},{"key":"2020021300191725300_REF41","unstructured":"Clark H, Yano T, Otuski T, Jaffe E, Shibata D, Raffeld M. Mutations in the coding region of C-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res. 1994;54: 3383-3386."},{"key":"2020021300191725300_REF42","unstructured":"Yano T, Sander C, Clark H, Dolezal V, Jaffe E, Raffeld M. Clustered mutations in the second exon of the Myc gene in sporadic Burkitt's lymphoma. Oncogene. 1993;8: 2741-1748."},{"key":"2020021300191725300_REF43","doi-asserted-by":"crossref","unstructured":"Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol. 1995; 13: 812-820.","DOI":"10.1200\/JCO.1995.13.4.812"},{"key":"2020021300191725300_REF44","doi-asserted-by":"crossref","unstructured":"Gaidano G, Ballerini P, Gong J, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991; 88: 5413-5217.","DOI":"10.1073\/pnas.88.12.5413"},{"key":"2020021300191725300_REF45","unstructured":"Bhatia K, Gutierrez M, Huppi K, Siwarski D, Magrath I. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 1992;52: 4273-4276."},{"key":"2020021300191725300_REF46","doi-asserted-by":"crossref","unstructured":"Katzenellenbogen R, Baylin S, Herman J. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93: 4347-4353.","DOI":"10.1182\/blood.V93.12.4347"},{"key":"2020021300191725300_REF47","doi-asserted-by":"crossref","unstructured":"Tepper C, Seldin M. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood. 1999;94: 1727-1737.","DOI":"10.1182\/blood.V94.5.1727"},{"key":"2020021300191725300_REF48","doi-asserted-by":"crossref","unstructured":"Klangby U, Okan I, Magnusson K, Wendland M, Lind P, Wiman K. P16\/INK4a and p15\/INK4b gene methylation and absence of p16\/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood. 1998;91: 1680-1687.","DOI":"10.1182\/blood.V91.5.1680"},{"key":"2020021300191725300_REF49","doi-asserted-by":"crossref","unstructured":"Murphy S, Bowman W, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (S Ig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4: 1732-1739.","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"2020021300191725300_REF50","doi-asserted-by":"crossref","unstructured":"Patte C, Phillip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9: 123-132.","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"2020021300191725300_REF51","doi-asserted-by":"crossref","unstructured":"Schwenn M, Blattner S, Lynch E, Weinstein H. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991;9: 133-138.","DOI":"10.1200\/JCO.1991.9.1.133"},{"key":"2020021300191725300_REF52","doi-asserted-by":"crossref","unstructured":"Bowman W, Shuster J, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996;14: 1252-1261.","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"2020021300191725300_REF53","doi-asserted-by":"crossref","unstructured":"Reiter A, Schrappe M, Ludwig W-D, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;90: 2471-2478.","DOI":"10.1182\/blood.V80.10.2471.2471"},{"key":"2020021300191725300_REF54","doi-asserted-by":"crossref","unstructured":"Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14: 925-934.","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"2020021300191725300_REF55","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Ludwig W-D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87: 495-508.","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"2020021300191725300_REF56","doi-asserted-by":"crossref","unstructured":"Thomas D, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17: 2461-2470.","DOI":"10.1200\/JCO.1999.17.8.2461"},{"key":"2020021300191725300_REF57","doi-asserted-by":"crossref","unstructured":"Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia. Cancer. 2002;94: 1492-1499.","DOI":"10.1002\/cncr.10365"},{"key":"2020021300191725300_REF58","doi-asserted-by":"crossref","unstructured":"Bernstein J, Coleman C, Strickler J, Dorfman R, Rosenberg S. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847-858.","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"2020021300191725300_REF59","doi-asserted-by":"crossref","unstructured":"Lopez T, Hagemeister F, McLaughlin P, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990;8: 615-622.","DOI":"10.1200\/JCO.1990.8.4.615"},{"key":"2020021300191725300_REF60","doi-asserted-by":"crossref","unstructured":"Longo D, Duffey P, Jaffe E, et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination therapy. J Clin Oncol. 1994;12: 2153-2159.","DOI":"10.1200\/JCO.1994.12.10.2153"},{"key":"2020021300191725300_REF61","doi-asserted-by":"crossref","unstructured":"Divine M, Lepage E, Briere J, et al. Is the small non-cleaved cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case controlled analysis. J Clin Oncol. 1996;14: 240-248.","DOI":"10.1200\/JCO.1996.14.1.240"},{"key":"2020021300191725300_REF62","unstructured":"Divine M, Cassasus P, Koscielny S, et al. Adult Burkitt lymphoma. A prospective multicenter trial with the LMB protocol. Proc Am Soc Clin Oncol [abstract]. 2000;19: 80."},{"key":"2020021300191725300_REF63","doi-asserted-by":"crossref","unstructured":"Todeschini G, Tecchio C, Degani D, et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma\/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol. 1997;8: S77-S81.","DOI":"10.1093\/annonc\/8.suppl_1.S77"},{"key":"2020021300191725300_REF64","unstructured":"Adde M, Shad A, Venzon D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998;25: 33-39."},{"key":"2020021300191725300_REF65","unstructured":"LaCasce A, Howard O, Li S, Fisher D, Neuberg D, Shipp M. The Magrath regimen is effective in older adults with Burkitt's and Burkitt-like lymphomas. Proc Am Soc Clin Oncol [abstract]. 2002;21: 1150."},{"key":"2020021300191725300_REF66","unstructured":"Cabanillas M, Thomas D, Cortes J, et al. Outcome with hyper-CVAD and rituximab in Burkitt (BL) and Burkitt-like (BLL) leukemia\/lymphoma. Proc Am Soc Clin Oncol [abstract]. 2003;22: 2309."},{"key":"2020021300191725300_REF67","doi-asserted-by":"crossref","unstructured":"Lee E, Petroni G, Schiffer C, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251. J Clin Oncol. 2001; 19: 4014-4022.","DOI":"10.1200\/JCO.2001.19.20.4014"},{"key":"2020021300191725300_REF68","unstructured":"Lee E, Pettoni G, Freter C, Johnson J, Schiffer C, Peterson B. Brief duration high intensity chemotherapy for patients with small non-cleaved lymphoma (IWF J) and FAB L3 acute lymphoblastic leukemia in adults: preliminary results of CALGB 9251. Proc Am Soc Clin Oncol [abstract]. 1997; 16."},{"key":"2020021300191725300_REF69","doi-asserted-by":"crossref","unstructured":"Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage: a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13: 359-372.","DOI":"10.1200\/JCO.1995.13.2.359"},{"key":"2020021300191725300_REF70","unstructured":"Schwenn M, Mahmoud H, Bowman W, Hutchison R, Kepner J, Murphy S. The addition of VP-Ifosfamide intensification did not improve event-free survival (EFS) for central nervous system (CNS) negative patients with advanced-stage small non-cleaved cell (SNCC) lymphoma or B-cell acute lymphoblastic leukemia (B-ALL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol [abstract]. 2001;20: 1465."},{"key":"2020021300191725300_REF71","doi-asserted-by":"crossref","unstructured":"Spreafico F, Massimino M, Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol. 2002;20: 2783-2788.","DOI":"10.1200\/JCO.2002.08.088"},{"key":"2020021300191725300_REF72","doi-asserted-by":"crossref","unstructured":"Nademanee A, Molina A, O'Donnell M, et al. Results of high-dose therapy and autologous bone marrow\/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International Index high and high-intermediate risk group. Blood. 1997;90: 3844-3852.","DOI":"10.1182\/blood.V90.10.3844"},{"key":"2020021300191725300_REF73","doi-asserted-by":"crossref","unstructured":"Sweetenham J, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone A. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma: outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14: 2465-2472.","DOI":"10.1200\/JCO.1996.14.9.2465"},{"key":"2020021300191725300_REF74","doi-asserted-by":"crossref","unstructured":"Hughes W, Armstrong D, Bodey G, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34: 730-751.","DOI":"10.1086\/339215"},{"key":"2020021300191725300_REF75","doi-asserted-by":"crossref","unstructured":"Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T. Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant. 2000;26: 1351-1354.","DOI":"10.1038\/sj.bmt.1702730"},{"key":"2020021300191725300_REF76","doi-asserted-by":"crossref","unstructured":"Grigg A, Seymour J. Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma. 2002;43: 889-892.","DOI":"10.1080\/10428190290017051"},{"key":"2020021300191725300_REF77","doi-asserted-by":"crossref","unstructured":"Peniket A, Ruiz de Elvira M, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31: 667-678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2020021300191725300_REF78","doi-asserted-by":"crossref","unstructured":"McMahon S, Wood M, Cole M. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol. 2000;20: 556-562.","DOI":"10.1128\/MCB.20.2.556-562.2000"},{"key":"2020021300191725300_REF79","doi-asserted-by":"crossref","unstructured":"Williams S, Gillan E, Knoppel E, Buzby J, Suen Y, Cairo M. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma. Ann Oncol. 1997;8: 25-30.","DOI":"10.1093\/annonc\/8.suppl_1.S25"},{"key":"2020021300191725300_REF80","doi-asserted-by":"crossref","unstructured":"Smith J, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J Natl Cancer Inst. 1998;90: 1146-1154.","DOI":"10.1093\/jnci\/90.15.1146"},{"key":"2020021300191725300_REF81","unstructured":"Orlowski R, Eswara J, Orlowski M, Dang C. Novel demonstration of tumor growth delay in a murine model of human Burkitt's lymphoma after treatment with a proteasome inhibitor. Proc Am Soc Clin Oncol [abstract]. 1998; 1717."},{"key":"2020021300191725300_REF82","doi-asserted-by":"crossref","unstructured":"Serafeim A, Holder M, Grafton G, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood. 2003;101: 3212-3219.","DOI":"10.1182\/blood-2002-07-2044"},{"key":"2020021300191725300_REF83","doi-asserted-by":"crossref","unstructured":"Serafeim A, Grafton G, Chamba A, et al. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood. 2002;99: 2545-2553.","DOI":"10.1182\/blood.V99.7.2545"},{"key":"2020021300191725300_REF84","doi-asserted-by":"crossref","unstructured":"Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without Human Immunodeficiency Virus infection. Cancer. 1998;82: 766-774.","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V"},{"key":"2020021300191725300_REF85","doi-asserted-by":"crossref","unstructured":"Hamilton-Dutoit S, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAS (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993; 82: 619-624.","DOI":"10.1182\/blood.V82.2.619.619"},{"key":"2020021300191725300_REF86","doi-asserted-by":"crossref","unstructured":"Subar M, Neri A, Inghirami G, Knowles D, Dalla-Favera R. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood. 1998;72: 667-671.","DOI":"10.1182\/blood.V72.2.667.667"},{"key":"2020021300191725300_REF87","doi-asserted-by":"crossref","unstructured":"Farrell C, Lee J, Shin E, Cebrat M, Cole P, Hayward S. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc Natl Acad Sci U S A. 2004;101: 4625-4630.","DOI":"10.1073\/pnas.0306482101"},{"key":"2020021300191725300_REF88","doi-asserted-by":"crossref","unstructured":"Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A. 2003;100: 14269-14274.","DOI":"10.1073\/pnas.2336099100"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3009\/1703253\/zh802204003009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3009\/1703253\/zh802204003009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T05:38:24Z","timestamp":1624513104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/10\/3009\/18728\/Adult-Burkitt-leukemia-and-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-02-0405","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}